Let’s say the mTNBC patients respond well to ler

Let’s say the mTNBC patients respond well to leronlimab and CYDY is granted BTD, would a licensing deal at that point be much more beneficial to CYDY .i.e a larger share of the profits? Or would it be something similar to HIV? Maybe there’s a chance CYDY can go it alone for mTNBC?

Does anyone have an idea of what the market, in terms of revenue, looks like for mTNBC? Obviously the market could be much, much larger considering other CCR5 cancers but that’s too much math for me.